Conceptus, Inc.
News and overview for Conceptus, Inc.
Conceptus to Present at the Piper Jaffray 21st Annual Healthcare Conference [Press Release]
Business Wire | 7 days 17 hours 49 minutes ago
Conceptus, Inc. (Nasdaq: CPTS), developer of the Essure® procedure, the first proven non-incisional permanent birth control method available, today announced that Mark Sieczkarek, president and chief executive officer, will present at the Piper Jaffray 21st Annual Healthcare Conference on Tuesday December 1, 2009, at 2:00 p.m. ET. The conference will be held at the New York Palace Hotel.
Conceptus to Continue Patent Infringement Suit against Adiana Permanent Contraception System [Press Release]
Business Wire | 15 days 10 hours 15 minutes ago
Conceptus, Inc. (Nasdaq: CPTS), developer of the Essure® procedure, the first proven non-incisional permanent birth control method available, today announced that the United Stated District Court, Northern District of California has denied Conceptus’ motion for a preliminary injunction prohibiting Hologic, Inc. (Nasdaq: HOLX) from importing, using, selling or offering to sell the Adiana system in the United States.
Court denies preliminary injunction against Hologic, Conceptus to continue patent infringement suit
News-Medical.Net | 14 days 23 hours 31 minutes ago
Conceptus, Inc. (Nasdaq: CPTS), developer of the Essure® procedure, the first proven non-incisional permanent birth control method available, today announced that the United Stated District Court, Northern District of California has denied Conceptus motion for a preliminary injunction prohibiting Hologic, Inc. (Nasdaq: HOLX) from importing, using, selling or offering to sell the Adiana system in the United States.
Conceptus to Present at the Lazard Capital Markets 6th Annual Healthcare Conference [Press Release]
Business Wire | 20 days 18 hours 19 minutes ago
Conceptus, Inc. (Nasdaq: CPTS), developer of the Essure® procedure, the first proven non-incisional permanent birth control method available, today announced that Mark Sieczkarek, president and chief executive officer, will present at the Lazard Capital Markets 6th Annual Healthcare Conference on Tuesday, November 17, 2009, at 2:10 p.m. ET. The conference will be held at the St. Regis Hotel in New York City.
Essure to Be Highlighted at 18th Annual Congress of the European Society for Gynaecological Endoscopy [Press Release]
Business Wire | 26 days 23 hours 49 minutes ago
Conceptus, Inc. (Nasdaq: CPTS), developer of the Essure® procedure, the first proven non-incisional permanent birth control method available, today announced that the clinical success of the Essure® procedure will be highlighted at the 18th Annual Congress of the European Society for Gynaecological Endoscopy (ESGE) in Florence, Italy from October 28-31, 2009.
Conceptus reports clinical success of its Essure non-incisional permanent birth control procedure
News-Medical.Net | 26 days 22 hours 33 minutes ago
Conceptus, Inc. (Nasdaq: CPTS), developer of the Essure® procedure, the first proven non-incisional permanent birth control method available, today announced that the clinical success of the Essure® procedure will be highlighted at the 18th Annual Congress of the European Society for Gynaecological Endoscopy (ESGE) in Florence, Italy from October 28-31, 2009.
Zacks Releases Four Powerful ''Buy'' Stocks: Conceptus, Inc., Nordstrom, Inc., Caterpillar, Inc. and Sabesp [Press Release]
Business Wire | 27 days 10 hours 49 minutes ago
Four free stock picks are being made available today on Zacks.com. The industry’s leading independent research firm highlights one Zacks #1 Rank Strong Buy or a Zacks #2 Rank Buy stock for each of the four main styles of investing: Aggressive Growth, Growth & Income, Momentum, and Value.
UPDATE 1-Conceptus Q3 profit tops market, ups '09 earnings view
Reuters | 34 days 10 hours 14 minutes ago
Oct 20 (Reuters) - Conceptus Inc (CPTS.O) posted a better-than-expected quarterly profit, helped by more doctors performing its permanent birth control method and cost savings, and raised its 2009 earnings view.
Renessa(R) Treatment for Female Incontinence Named Most Promising New Product [Press Release]
PRNewswire | 42 days 14 hours 49 minutes ago
...13 /PRNewswire/ -- Novasys Medical, Inc., a developer of innovative therapies...the standard of medical care, including Conceptus' Essure device, JNJ/Cordis' drug eluting...3,000 patients. Novasys Medical, Inc. is a privately held, venture-backed...
Novasys Medical's Renessa named the most promising new product for 2009
News-Medical.Net | 42 days 2 hours 30 minutes ago
Novasys Medical, Inc., a developer of innovative therapies in women's health, announced today that its Renessa® non-surgical treatment for female stress urinary incontinence (SUI) was inducted into the Phoenix Hall of Fame as the 2009 Most Promising New Product at the Phoenix Medical Device and Diagnostic Conference for Chief Executive Officers
Novasys Medical's Renessa for treating female incontinence named most promising new product for 2009
News-Medical.Net | 42 days 18 hours 28 minutes ago
Novasys Medical, Inc., a developer of innovative therapies in women's health, announced today that its Renessa® non-surgical treatment for female stress urinary incontinence (SUI) was inducted into the Phoenix Hall of Fame as the 2009 Most Promising New Product at the Phoenix Medical Device and Diagnostic Conference for Chief Executive Officers
11 Results
Sign up for AdvaMed SmartBrief
Company Overview
| Company: | Conceptus, Inc. |
|---|---|
| Industry: | Medical Devices |
| Website: | http://www.conceptus.com |
Though you might not think so from the name, Conceptus makes products to hinder conception, not help it along. The company makes and sells Essure, a birth control system that permanently blocks conception with a micro-coil device implanted in the fallopian tube. Essure can be inserted during an outpatient procedure that takes 15 minutes and does not require general anesthesia. Conceptus markets the product primarily to gynecologists in the US through a direct sales force and internationally through distributors in Australia, Canada, France, Spain, and the UK.
Key Numbers
| Sales in U.S. Dollars (mil.) | 102 (2008) |
|---|---|
| One-year % Growth in Sales | 58.2 (2008) |
| Net Income in U.S. Dollars (mil.) | -0.1 (2008) |
| One-year % Growth in Net Income | 0.0 (2008) |
| Number of Employees | 0 (0) |
| One-year % Growth in Number of Employees | 0.0 (0) |
| Fiscal Year-End | December |